Allergy Therapeutics (HHU) Income Statement
Allergy Therapeutics Income Statement
Last quarter (Q2 2026), Allergy Therapeutics's total revenue was $36.28M, an increase of 8.07% from the same quarter last year. In Q2, Allergy Therapeutics's net income was $-19.92M. See Allergy Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| $ 55.04M | $ 55.20M | $ 59.59M | $ 72.77M | $ 84.33M | |
| $ 25.13M | $ 29.74M | $ 32.69M | $ 48.95M | $ 61.80M | |
| $ 54.63M | $ 64.99M | $ 72.90M | $ 61.95M | $ 59.16M | |
| Depreciation and Amortization | $ 4.17M | $ 4.32M | $ 4.22M | $ 4.17M | $ 4.13M |
| $ -29.43M | $ -30.74M | $ -36.24M | $ -8.69M | $ 7.61M | |
| $ -29.50M | $ -35.26M | $ -34.85M | $ -13.00M | $ 4.03M | |
| $ -10.94M | $ -3.91M | $ -7.77M | $ -396.00K | $ -374.00K | |
| $ -40.44M | $ -39.17M | $ -42.62M | $ -13.40M | $ 3.66M | |
| $ -40.13M | $ -40.22M | $ -43.07M | $ -13.78M | $ 2.89M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.01 | $ -0.01 | $ -0.06 | $ -0.02 | $ 0.00 |
| Diluted EPS | $ -0.01 | $ -0.01 | $ -0.06 | $ -0.02 | $ 0.00 |
| Weighted Average Shares Outstanding | 4.77B | 3.74B | 669.84M | 642.99M | 671.32M |
| Weighted Average Shares Outstanding (Diluted) | 4.77B | 3.74B | 670.36M | 642.99M | 676.66M |
Currency in GBP